No abstract is provided for this article.
A nonlinear finite element model of the triple-bay prestressed stayed column is developed within the commercial software ABAQUS. A linearly obtained ‘optimal prestress’ that maximizes the critical buckling load is investigated since this quantity has been demonstrated in previous work on single-bay prestressed columns to provide a lower bound to the actual maximum load carrying capacity when compared to results from physical experiments and nonlinear modelling. The ratio of the crossarm to column length, the diameter of the cable stays and the ratio of the prestressing force to the linear optimal prestress are varied. Measures for the relative cost of the main column and the stays are defined and it is determined that the true optimal prestress is generally higher than the linearly obtained quantity but by a reduced factor when compared to an equivalent study for the single-bay column case.
Despite the advances in the treatment of patients with coronary artery disease, sudden cardiac death is still unacceptably prevalent. Patients with ischemic heart disease usually require a combination of therapies (drugs and coronary intervention) and may continue to experience symptoms. Recently, numerous percutaneous interventional treatments and diagnostic tools have been developed to diagnose the vulnerable plaque and to treat the large number of patients with myocardial ischemia. Ongoing research on the use of drug eluting stents, catheter based bypass graft (percutaneous approaches that use the adjacent venous circulation to bypass an obstructed artery and stent-based approach for ventricle to coronary artery bypass), therapeutic angiogenesis and myogenesis, and the catheter based devices to detect the plaque vulnerability and composition (lipid-rich atheromatous core, thin fibrous cap, and expansive vessel remodeling) may result in additional diagnostic and therapeutic options for patients with coronary artery disease.
Leukotriene B 4 (LTB 4 ) stimulation of guinea‐pig peritoneal eosinophils, induced a biphasic activation of the NADPH oxidase composed of a rapid (<3 min) phase mediated by non‐adherent cells and a sustained (3 – 120 min) phase mediated by CD11b/CD18 adherent eosinophils. Studies were undertaken to compare the intracellular mechanism that mediate these responses. SB 203580 and PP1, inhibitors of p38 mitogen‐activated protein (MAP) kinase and the src‐family protein tyrosine kinases, respectively caused concentration‐dependent attenuation of both the rapid (SB203580: pD 2 =−6.31; PP1: pD 2 =−5.50) and sustained (SB203580: pD 2 =−6.50; PP1: pD 2 =−5.73) phases. Similarly, the MAP kinase kinase‐1 inhibitor, PD098059 produced partial inhibition of the both phases of superoxide generation. The protein kinase C (PKC) inhibitors Ro‐31 8220, GF 109203X and Gö 6976 attenuated the rapid NADPH oxidase response (pD 2 s=−6.10, −6.72, −6.15 respectively) and, to a lesser extent, (pD 2 s=−5.54, −6.02, −6.51 respectively) the sustained phase. An inhibitor of phosphatidylinositol 3‐kinase (PtdIns 3‐kinase), wortmannin caused concentration dependent attenuation of the sustained (pD 2 =−8.68) but not rapid phase of superoxide generation. In contrast, the syk kinase inhibitor, piceatannol abolished the rapid (pD 2 =−6.43) but not sustained respiratory responses. This study demonstrates that LTB 4 ‐induced superoxide generation from adherent and non‐adherent eosinophils is mediated via both common (p38 MAP kinase, MEK‐1, PKC and the src kinases) and divergent intracellular pathways (syk kinases and PtdIns 3‐kinase). This suggests the possibility of therapeutic intervention to selective attenuate activation of adherent tissue eosinophils. British Journal of Pharmacology (2001) 134 , 797–806; doi: 10.1038/sj.bjp.0704314
Acute severe asthma in adults Recognition and assessment in hospital Features of acute severe asthma * Can't complete sentences in one breath * Respirations 225 breaths/min * Pulse 11O beats/min * Peak expiratory flow (PEF) s 50% of predicted * or best Life threatening features * PEF <33% of predicted or best * Silent chest, cyanosis, or feeble respiratory effort * Bradycardia or hypotension * Exhaustion, confusion, or coma If a patient has any of these features, then measure arterial blood gases.Markers of a very severe, life threatening attack: * Normal (5-6 kPa, 36-45 mm Hg) or high Faco2 * Severe hypoxia: Pao2 <8 kPa (60 mm Hg) irrespective of treatment with oxygen * A low pH (or high H+) No other investigations are needed for immediate management.